Drug Profile
Conteltinib - Centaurus Biopharma
Alternative Names: CT-707; SY-707Latest Information Update: 18 Oct 2022
Price :
$50
*
At a glance
- Originator Beijing Sailin Tai Pharmaceutical; Centaurus Biopharma
- Developer Beijing Sailin Tai Pharmaceutical; Centaurus Biopharma; Shouyao Holdings
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion kinase 1 inhibitors; Insulin-like growth factor-I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 18 Oct 2022 Phase-III clinical trials in Non-small cell lung cancer in China (unspecified route) (Shouyao Holdings pipeline, October 2022)
- 18 Oct 2022 Phase-III clinical trials in Pancreatic cancer in China (unspecified route) (Shouyao Holdings pipeline, October 2022)
- 11 Aug 2022 Phase-I/II clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (unspecified route) (NCT05580445)